{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T04:10:24Z","timestamp":1651032624143},"reference-count":23,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2015]]},"DOI":"10.7883\/yoken.jjid.2014.202","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T02:47:15Z","timestamp":1421808435000},"page":"263-267","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China"],"prefix":"10.7883","volume":"68","author":[{"given":"Hongbin","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqiang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking University People's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant <i>Klebsiella pneumoniae<\/i> acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028-33.","DOI":"10.1128\/AAC.01020-07"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Perry CM, Ibbotson T. Biapenem. Drugs. 2002;62:2221-34.","DOI":"10.2165\/00003495-200262150-00005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43:727-37.","DOI":"10.1128\/AAC.43.4.727"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Inouye S, Goi H, Watanabe T, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984;26:722-9.","DOI":"10.1128\/AAC.26.5.722"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lee J, Kim CK, Roh KH, et al. In vitro activity of arbekacin against clinical isolates of <i>Staphylococcus<\/i> species and gram-negative bacilli. Korean J Lab Med. 2007;27:292-7. Korean.","DOI":"10.3343\/kjlm.2007.27.4.292"},{"key":"6","unstructured":"6. Kuwabara M, Kusano N, Shimizu E, et al. Epidemiology and drug susceptibility of <i>Pseudomonas aeruginosa<\/i> strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region. Jpn J Antibiot. 2011;64:97-108."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bonfiglio G, Maccarone G, Mezzatesta ML, et al. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates. Chemotherapy. 1997;43:393-403.","DOI":"10.1159\/000239597"},{"key":"8","unstructured":"8. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 6th ed. Document M7-A6. Wayne, PA: NCCLS; 2003."},{"key":"9","unstructured":"9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 23rd ed. Document M100-S23. Wayne, PA: CLSI; 2013."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1993;37:2009-16.","DOI":"10.1128\/AAC.37.9.2009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jia B, Lu P, Huang W, et al. A multicenter, randomized controlled clinical study on biapenem and imipenem\/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010;56:285-90.","DOI":"10.1159\/000319952"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li H, Zhang J, Liu Y, et al. Molecular characteristics of carbapenemase-producing enterobacteriaceae in China from 2008 to 2011: predominance of KPC-2 enzyme. Diagn Microbiol Infect Dis. 2014;78:63-5.","DOI":"10.1016\/j.diagmicrobio.2013.10.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yang Q, Wang H, Sun H, et al. Phenotypic and genotypic characterization of enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother. 2010;54:573-7.","DOI":"10.1128\/AAC.01099-09"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate &beta;-lactamase inhibitor RPX7009 against carbapenem-resistant enterobacteriaceae. J Antimicrob Chemother. 2013;68:1825-31.","DOI":"10.1093\/jac\/dkt118"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tanaka N, Matsunaga K, Hirata A, et al. Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic. Antimicrob Agents Chemother. 1983;24:797-802.","DOI":"10.1128\/AAC.24.5.797"},{"key":"16","unstructured":"16. Lerma M, Cebri&aacute;n L, Gim&eacute;nez M, et al. &beta;-lactam susceptibility of <i>Escherichia coli<\/i> isolates from urinary tract infections exhibiting different resistance phenotypes. Rev Esp Quimioter. 2008;21:149-52."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huelves L, Gracia M, Del Prado G, et al. Efficacy of cefminox compared with amoxicillin\/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of <i>Escherichia coli<\/i> and one strain of <i>Bacteroides fragilis<\/i>. Int J Antimicrob Agents. 2006;28:151-3.","DOI":"10.1016\/j.ijantimicag.2006.05.022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003&ndash;2008. Int J Antimicrob Agents. 2010;35:227-34.","DOI":"10.1016\/j.ijantimicag.2009.11.010"},{"key":"19","unstructured":"19. Ubukata K, Chiba N, Kobayashi R, et al. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of <i>Pseudomonas aeruginosa<\/i>. Jpn J Chemother. 2002;50:1-10. Japanese."},{"key":"20","unstructured":"20. Hiraishi T, Miyata A, Takata T, et al. Bactericidal activity of biapenem against various efflux system mutants of <i>Pseudomonas aeruginosa<\/i>. Jpn J Antibiot. 2002;55:67-76."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Raymond NJ, Bremner DA. The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother. 1995;35:681-6.","DOI":"10.1093\/jac\/35.5.681"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ishii Y, Eto M, Mano Y, et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-&beta;-lactamase inhibitor, against metallo-&beta;-lactamase- producing <i>Pseudomonas aeruginosa<\/i> clinical isolates. Antimicrob Agents Chemother. 2010;54:3625-9.","DOI":"10.1128\/AAC.01397-09"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Araoka H, Baba M, Tateda K, et al. In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant <i>Pseudomonas aeruginosa<\/i> in Japan. Jpn J Infect Dis. 2012;65:84-7.","DOI":"10.7883\/yoken.65.84"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T03:48:51Z","timestamp":1651031331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/68\/4\/68_JJID.2014.202\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2014.202","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}